/PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or
"the Company"), (AIM: AP.L), the Medical Technology Company focussed on the
Woundcare, Oralcare and Cardiovascular Health markets today announces the
successful development of an effective nano-fibre based delivery platform for
its patented m.doc(TM) based woundcare technology.
This month's final haemostasis efficacy studies on m.doc(TM) based
nano-fibre woundcare prototypes have proven both effective and efficient
haemostasis. This follows nine months of technical evaluation and prototype
testing with Alltracel's nanotechnology development partner ELMARCO s.r.o.
("Elmarco") of the Czech Republic.
Manufacturing discussions are now taking place with existing and new
manufacturing partners to incorporate this technology into existing and new
woundcare delivery systems for both the consumer and professional markets.
Elmarco (www.elmarco.cz) is a specialist R&D and manufacturing company
that has developed, in conjunction with the Technical University of Liberic,
a novel proprietary & patented process for spinning polymers into nano-scale
fibres for a range of industrial, chemical, micro-electronic and bio-medical
Alltracel's CEO, Tony Richardson, commented: "Alltracel has always been
committed to innovation and the development of our proprietary m.doc(TM)
technology. We are extremely pleased to have worked closely with our
development partner Elmarco in undertaking this research which has resulted
in a breakthrough in the advancement of nano-fibre delivery systems.
This novel nano-fibre based m.doc(TM) delivery platform enables not only
the development of new m.doc(TM) products and delivery systems but also the
cost effective re-engineering of existing m.doc(TM) delivery systems.
We are now focussed on manufacturing partnership discussions for both
consumer and professional woundcare products and are targeting to have the
first m.doc(TM) based nano-fibre products on the market this year."
Notes to Editors:
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc
is a Medical Technology Company focussed on the Woundcare, Oralcare and
Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a
commercial office in London, England; R&D subsidiary in the Czech Republic
and manufacturing facilities in Shenzhen, China. Alltracel was founded in
1996 and listed on London's Alternative Investment Market in July 2001.
Alltracel's has a number of patents in the areas of polysaccharide
manipulation and PTFE processes and products as well as a significant
collaborative R&D programme in place focussed on its markets.
In the Woundcare market m.doc(TM) (Micro Dispersed Oxidized Cellulose;
(www.m-doc.com)) is the trading name given to Alltracel's patented technology
which is proven as an effective and efficient haemostatic (blood-stopping)
- In the consumer Woundcare sector m.doc(TM) is currently being marketed
as the leading stops bleeding ingredient brand within recognized woundcare,
and relevant first-aid brands worldwide.
- Alltracel's woundcare technology is also currently poised for entry
into the professional Woundcare and specialist Oralcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com)
has developed a novel bioactive compound that, following two years of
scientific research including in vitro, pre-clinical and clinical trials,
indicates cardiovascular health (CVH) benefits on its own and in combination
with existing CVH products.
Alltracel's patented process utilises a derivative of cellulose fibre to
produce a bioactive with scientifically proven properties that aid CVH;
specifically lowering LDL cholesterol, reducing blood glucose levels and
helping to prevent arterial plaque build up.
The end result is a pioneering, value-adding bioactive that can enhance
and differentiate current cardiovascular health products and that can add
benefit to current non-health benefiting nutritious finished foods.
- Further efficacy, dosage, timing/phasing and combination (with other
bio-actives) studies to determine optimum delivery systems, formats and
combinations in both the functional foods and pharmaceutical markets are
- Development discussions with potential partners in the functional foods
and pharmaceutical sectors in the EU, Asia and North America have commenced.
m.doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
For Further Information Contact:
Dublin: Kathy Wray
London: Sarah MacLeod
New York: Sean Leous
SOURCE Alltracel Pharmaceuticals Plc.